Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)

Azka Latif, Aheli Arce Gastelum, Akshat Sood, Joseph Thilumala Reddy

Research output: Contribution to journalArticlepeer-review

Abstract

We report a case of euglycaemic diabetic ketoacidosis (EDKA) in a 43-year-old woman with type 2 diabetes mellitus who presented to the emergency department with problems of vomiting, cough, shortness of breath and generalised weakness after following a ketogenic diet for 2 weeks. Therapy with sodium glucose transport protein-2 empagliflozin had been started 2 months prior. Initial evaluation revealed high anion gap metabolic acidosis with blood glucose level of 169mg/dL. Treatment for EDKA with fluid resuscitation, intravenous insulin and dextrose resolved her acidosis and symptoms in less than 24hours. Empaglifozin was discontinued on discharge. This entity represents a diagnostic challenge since the differential diagnosis is broad with a potentially misleading clinical presentation that can result in delayed diagnosis and adverse outcomes including acute kidney injury, multiple electrolyte abnormalities, cerebral oedema, acute respiratory distress syndrome, shock and death.

Original languageEnglish (US)
Pages (from-to)93-95
Number of pages3
JournalDrug and Therapeutics Bulletin
Volume59
Issue number6
DOIs
StatePublished - Jun 1 2021

All Science Journal Classification (ASJC) codes

  • Pharmacology (medical)

Fingerprint

Dive into the research topics of 'Euglycaemic diabetic ketoacidosis in a 43-year-old woman with type 2 diabetes mellitus on SGLT-2 inhibitor (empagliflozin)'. Together they form a unique fingerprint.

Cite this